Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled rhDNase1 in Non-Ventilated COVID-19
NCT04409925Phase 1Completed
- Sponsor
- McGill University Health Centre
- Start
- Dec 2020
- Primary completion
- Apr 2021
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dornase alfa in coronavirus disease 2019 (COVID-19), sponsored by McGill University Health Centre. Primary endpoint: Safety of inhaled rhDNase1 at 9 months. Started Dec 2020; status: completed.
02
Drugs
dornase alfa
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04409925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04409925.